Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05932290 · FLOW

Participant flow

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma · Source last updated 2024-10-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Eligible participants with triple-class refractory multiple myeloma (TCR MM), who were B-cell maturation antigen (BCMA) naïve, who were enrolled between 2 February 2021 to 07 January 2022 and who were treated with elranatamab in study C1071003 were included.
    id
    FG000
    title
    C1071003 Cohort A
  2. description
    Eligible participants with TCR MM who were treated with standard of care (SOC) therapies in real world clinical practice setting, identified from COTA database were included. This arm served as external control arm.
    id
    FG001
    title
    RWD: COTA
  3. description
    Eligible participants with TCR MM who were treated with SOC therapies in real world clinical practice setting, identified from Flatiron Health database were included. This arm served as external control arm.
    id
    FG002
    title
    RWD: Flatiron Health
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        239
      3. group Id
        FG002
        num Subjects
        152
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        239
      3. group Id
        FG002
        num Subjects
        152
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
This retrospective cohort study used participant level data from study C1071003 (NCT04649359), and external control arms identified from real world data (RWD) sources.
Complete source fields
groups
  1. description
    Eligible participants with triple-class refractory multiple myeloma (TCR MM), who were B-cell maturation antigen (BCMA) naïve, who were enrolled between 2 February 2021 to 07 January 2022 and who were treated with elranatamab in study C1071003 were included.
    id
    FG000
    title
    C1071003 Cohort A
  2. description
    Eligible participants with TCR MM who were treated with standard of care (SOC) therapies in real world clinical practice setting, identified from COTA database were included. This arm served as external control arm.
    id
    FG001
    title
    RWD: COTA
  3. description
    Eligible participants with TCR MM who were treated with SOC therapies in real world clinical practice setting, identified from Flatiron Health database were included. This arm served as external control arm.
    id
    FG002
    title
    RWD: Flatiron Health
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        239
      3. group Id
        FG002
        num Subjects
        152
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        239
      3. group Id
        FG002
        num Subjects
        152
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
This retrospective cohort study used participant level data from study C1071003 (NCT04649359), and external control arms identified from real world data (RWD) sources.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice